Cardiovascular disease Circulatory System Cardiovascular disease, unspecified
Conditions
Interventions
This is a step-wedge cluster randomised controlled trial. Targeted case finding is being implemented in general practices. Practices are randomised to early (intervention) or later implementation (con
Sponsors
University Hospitals Birmingham NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participating practices are identified by the participating primary care trusts. Patients for inclusion in the prevention programme are identifed as follows. They must be registered at a participating practice. They must be aged between 35 and 74 and must not currently have coronary heart disease (CHD), not be on the diabetic register and not be currently receiving antihypertensive or statin treatment. From these patients are identified all those patients in whom a combination of risk factors indicates they are likely to be at greater than 20% ten-year risk of cardiovascular disease. These patients are considered eligible for inclusion in the cardiovascular prevention programme. These patients will be identified from primary care electronic medical records. In summary: 1. Patients (both males and females) aged between 35 and 74 2. Patients who do not have CHD 3. Patients who are not diabetic 4. Patients who are not receiving antihypertensives or statins 5. Patients who are likely to be at greater than 20% ten-year CVD risk
Exclusion criteria
Exclusion criteria: Patients who in the opinion of the practice staff are unable to benefit from cardiovascular risk factor assessment. For example, patients who are terminally ill. In practice this means that once a list has been created of individuals who are untreated high risk patients are eligible to be invited for cardiovascular risk factor assessment, practice staff will review the list and identify patients who are known to be terminally ill or otherwise unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of eligible patients started on preventive treatment (aspirin, antihypertensives and statins). All primary and secondary outcomes will be assessed at 3 months, 6 months and 1 year after the start of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in blood pressure, total cholesterol, HDL cholesterol and smoking status Process outcomes: 2. Numbers of persons attending for CVD risk factor assessment 3. Numbers of those assessed who are confirmed as being eligible for treatment All primary and secondary outcomes will be assessed at 3 months, 6 months and 1 year after the start of the study. | — |
Countries
United Kingdom
Outcome results
None listed